ESCAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines and in the Union list of critical medicines.
Saved in:
| Title: | ESCAP endorses the inclusion of methylphenidate in the WHO model lists of essential medicines and in the Union list of critical medicines. |
|---|---|
| Authors: | Cortese, Samuele, Coghill, David, Fegert, Joerg M., Mattingly, Gregory W., Rohde, Luis A., Wong, Ian C.K., Faraone, Stephen V. |
| Source: | European Child & Adolescent Psychiatry. May2024, Vol. 33 Issue 5, p1605-1608. 4p. |
| Subjects: | World Health Organization, Medical protocols, Essential drugs, Attention-deficit hyperactivity disorder, Drug approval, Methylphenidate, Public health, Union catalogs, Comorbidity, Medical care costs |
| Abstract: | The article focuses on the economic and health impacts of Attention-Deficit/Hyperactivity Disorder (ADHD) and highlights the debate regarding the inclusion of methylphenidate in critical medication lists. Topics include the substantial societal costs of ADHD, the effectiveness and safety of methylphenidate in managing the disorder, and the concerns about its exclusion from the World Health Organization's (WHO) Essential Medicines List and the European Union's Union List of critical medicines. |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
